28.07.2011 • Newssales and profitsQ2 2011DuPont

DuPont's Q2 Sales up 17% per Share

DuPont reported that its second-quarter net income attributable to the company rose to $1.218  billion or $1.29 per share, from $1.159 billion or $1.26 per share in the same quarter last year. Second-quarter 2011 earnings were $1.37 per share, up 17% from $1.17 per share in the prior year, excluding significant items from both periods.

Analysts polled by Thomson Reuters expected the company to report earnings of $1.34 per share. Analysts' estimates typically exclude special items.
Net sales for the quarter rose to $10.26 billion from $8.62 billion in the prior year quarter. Six analysts had consensus revenue estimate of $9.86
billion for the quarter.

The company increased its full-year 2011 earnings outlook, excluding significant items, to a range of $3.90 to $4.05 per share.

The increase reflects strong second-quarter results, the expectation for continued global economic growth and about $0.05 per share full-year operating earnings from Danisco on an underlying basis. Prior guidance was a range of $3.65 to $3.85 per share, excluding the impact of Danisco. Analysts expect the company to report earnings of $3.87 per share for fiscal 2011.

The company's estimate for the impact of the Danisco acquisition on full-year reported earnings is now a reduction of $.18 to $.29 per share, versus the previous estimate of a $0.30 to $0.45 per share reduction.

 

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.